• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Opiant Pharmaceuticals Inc. (Amendment)

    2/15/23 1:19:28 PM ET
    $OPNT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OPNT alert in real time by email
    SC 13G/A 1 d449015dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Opiant Pharmaceuticals, Inc.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class Securities)

    683750103

    (CUSIP Number)

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosure provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     

     

     


    CUSIP No. 683750103       Page 2 of 9 Pages

     

      1    

      NAME OF REPORTING PERSONS.

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).

     

      Western Standard, LLC

      26-2921385

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (A)  ☐        (B)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      California

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      424,080

       6  

      SHARED VOTING POWER

     

      0

       7  

      SOLE DISPOSITIVE POWER

     

      424,080

       8  

      SHARED DISPOSITIVE POWER

     

      0

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      424,080

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      8.2%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      IA


    CUSIP No. 683750103       Page 3 of 9 Pages

     

      1    

      NAME OF REPORTING PERSONS.

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).

     

      Eric D. Andersen

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (A)  ☐        (B)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States of America

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      424,080

       6  

      SHARED VOTING POWER

     

      0

       7  

      SOLE DISPOSITIVE POWER

     

      424,080

       8  

      SHARED DISPOSITIVE POWER

     

      0

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      424,080

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      8.2%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      IN, HC


    CUSIP No. 683750103       Page 4 of 9 Pages

     

      1    

      NAME OF REPORTING PERSONS.

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).

     

      Western Standard Partners, L.P.

      26-2921468

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (A)  ☐        (B)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      339,161

       6  

      SHARED VOTING POWER

     

      0

       7  

      SOLE DISPOSITIVE POWER

     

      339,161

       8  

      SHARED DISPOSITIVE POWER

     

      0

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      339,161

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      6.6%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      PN


          Page 5 of 9 Pages

     

    Item 1.

     

      (a)

    Name of Issuer

    Opiant Pharmaceuticals, Inc.

     

      (b)

    Address of Issuer’s Principal Executive Offices

    233 Wilshire Blvd., Suite 400, Santa Monica, CA 90401

     

    Item 2.

     

      (a)

    Name of Person Filing

    This Schedule 13G is being filed on behalf of Western Standard, LLC, Eric D. Andersen, and Western Standard Partners, L.P. (each, a “Reporting Person”).

     

      (b)

    Address of Principal Business office or, if None, Residence

    For each Reporting Person,

    5900 Wilshire Blvd, Suite 650, Los Angeles, California 90036

     

      (c)

    Citizenship

    Western Standard, LLC is a California limited liability company

    Western Standard Partners, L.P. is a Delaware limited partnership

    Mr. Andersen is a United States citizen

     

      (d)

    Title of Class of Securities

    Common Stock, par value $0.001 per share

     

      (e)

    CUSIP Number

    683750103

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a)

    ☐   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78c).

     

      (b)

    ☐   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

      (c)

    ☐   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

      (d)

    ☐   Investment company registered under section 8 of the Investment Company Act (15 U.S.C. 80a-8).

     

      (e)

    ☐   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E).


          Page 6 of 9 Pages

     

      (f)

    ☐   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(ii)(F).

     

      (g)

    ☐   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G).

     

      (h)

    ☐   A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

      (i)

    ☐   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company      Act of 1940 (15 U.S.C. 80a-3).

     

      (j)

    ☐   Group in accordance with § 240.13d-1(b)(ii)(J).

     

    Item 4.

    Ownership

    For each of Western Standard, LLC and Eric A. Andersen:

     

      (a)

    Amount beneficially owned: 424,080 (the “Shares”) **

     

      (b)

    Percent of class: 8.2% *

     

      (c)

    Number of shares to which the Reporting Person has:

     

      (i)

    Sole power to vote or to direct the vote: 424,080

     

      (ii)

    Shared power to direct the vote: 0

     

      (iii)

    Sole power to dispose or to direct the disposition of: 424,080

     

      (iv)

    Shared power to dispose or to direct the disposition of: 0

    For each of Western Standard Partners, L.P.:

     

      (a)

    Amount beneficially owned: 339,161

     

      (b)

    Percent of class: 6.6%*

     

      (c)

    Number of shares to which the Reporting Person has:

     

      (i)

    Sole power to vote or to direct the vote: 339,161

     

      (ii)

    Shared power to direct the vote: 0

     

      (iii)

    Sole power to dispose or to direct the disposition of: 339,161

     

      (iv)

    Shared power to dispose or to direct the disposition of: 0

     

    *

    Percentage calculated based on 5,167,814 shares of Common Stock outstanding as of November 10, 2022, as reported in the issuer’s most recent Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022, as filed with the Securities and Exchange Commission on November 14, 2022.


          Page 7 of 9 Pages

     

    **

    Western Standard, LLC, in its capacity as investment adviser to Western Standard Partners, L.P. and another private investment fund (the “Funds”), may be deemed to beneficial own the Shares owned by the Funds due to its power to direct the disposition and voting of the Shares owned by the Funds. Eric D. Andersen is the Managing Member of Western Standard, LLC and may also be deemed to beneficially own the Shares owned by the Funds. Pursuant to Rule 13d-4, each of Western Standard LLC and Eric D. Andersen disclaims beneficial ownership of the securities owned by the Funds, except to the extent of its or his pecuniary interest in the Shares.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class securities, check the following ☐

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Item 8.

    Identification and Classification of Members of the Group.

     

    Item 9.

    Notice of Dissolution of Group.

     

    Item 10.

    Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


          Page 8 of 9 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 15, 2023

     

    Western Standard Partners, L.P.
    By: Western Standard, LLC, its General Partner
    By:  

    /s/ Eric D. Andersen

      Eric D. Andersen, Managing Member
    Western Standard, LLC
    By:  

    /s/ Eric D. Andersen

      Eric D. Andersen, Managing Member
     

    /s/ Eric D. Andersen

      Eric D. Andersen
    Get the next $OPNT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OPNT

    DatePrice TargetRatingAnalyst
    12/9/2021$42.00Outperform
    Oppenheimer
    More analyst ratings

    $OPNT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Silver Gabrielle Alison returned $466,860 worth of shares to the company (23,343 units at $20.00), closing all direct ownership in the company

      4 - OPIANT PHARMACEUTICALS, INC. (0001385508) (Issuer)

      3/3/23 9:27:04 AM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Collard Craig A returned $1,116,440 worth of shares to the company (55,822 units at $20.00), closing all direct ownership in the company

      4 - OPIANT PHARMACEUTICALS, INC. (0001385508) (Issuer)

      3/3/23 9:25:03 AM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Ruth Matthew R. returned $638,320 worth of shares to the company (31,916 units at $20.00) and was granted 2,000 shares, closing all direct ownership in the company

      4 - OPIANT PHARMACEUTICALS, INC. (0001385508) (Issuer)

      3/3/23 9:22:53 AM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OPNT
    SEC Filings

    See more
    • SEC Form 15-12G filed by Opiant Pharmaceuticals Inc.

      15-12G - OPIANT PHARMACEUTICALS, INC. (0001385508) (Filer)

      3/13/23 6:15:56 AM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Opiant Pharmaceuticals Inc.

      EFFECT - OPIANT PHARMACEUTICALS, INC. (0001385508) (Filer)

      3/10/23 12:15:14 AM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Opiant Pharmaceuticals Inc.

      EFFECT - OPIANT PHARMACEUTICALS, INC. (0001385508) (Filer)

      3/10/23 12:15:06 AM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OPNT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for OPVEE issued to OPIANT PHARMACEUTICALS INC

      Submission status for OPIANT PHARMACEUTICALS INC's drug OPVEE (ORIG-1) with active ingredient NALMEFENE has changed to 'Approval' on 05/22/2023. Application Category: NDA, Application Number: 217470, Application Classification: Type 3 - New Dosage Form

      5/24/23 11:39:07 AM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • May 22, 2023 - FDA Approves Prescription Nasal Spray to Reverse Opioid Overdose

      For Immediate Release: May 22, 2023 Today, the U.S. Food and Drug Administration approved Opvee, the first nalmefene hydrochloride nasal spray for the emergency treatment of known or suspected opioid overdose in adults and pediatric patients 12 years of age and older. This is the first FDA approval of nalmefene hydrochloride nasal spray for health care and community use. “The agency continues to advance the FDA

      5/22/23 4:58:14 PM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for OPVEE (nalmefene) issued to OPIANT PHARMACEUTICALS INC

      Submission status for OPIANT PHARMACEUTICALS INC's drug OPVEE (nalmefene) (ORIG-1) with active ingredient OPVEE (nalmefene) has changed to 'Approval' on 05/22/2023. Application Category: NDA, Application Number: 217470, Application Classification: Type 3 - New Dosage Form

      5/22/23 4:51:13 PM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OPNT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Deepwatch Names Mel Wesley as Chief Financial Officer

      Successful finance and cybersecurity industry veteran to support rapid growth Deepwatch, the leader in advanced managed detection and response (MDR) security, announced today the appointment of Mel Wesley as Chief Financial Officer (CFO). Wesley is a seasoned finance executive with over 25 years of experience in financial planning, analysis, and operational finance, with a proven track record of driving growth and building high-performance finance teams. For the past 18 years, he has served as CFO for publicly traded and private technology companies. As Deepwatch's CFO, Wesley will support the Company during hyper-growth while overseeing finance, legal and corporate development. This press

      2/21/23 10:00:00 AM ET
      $OPNT
      $SCOR
      $FEYE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Business Services
      Consumer Discretionary
    • Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC

      CFIUS clearance represents the final required regulatory approval to complete the proposed mergerCompletion remains subject to the approval of Opiant stockholders; a special stockholder meeting to approve the acquisition will be held on March 1, 2023Indivior and Opiant continue to anticipate completing the proposed merger in the first quarter of 2023 SANTA MONICA, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals Inc. (NASDAQ:OPNT) announced today that the Committee on Foreign Investment in the United States (CFIUS) approved the previously announced Merger Agreement (the Agreement) for Opiant to be acquired by Indivior PLC (LSE: INDV). Following the expiration of the waiti

      2/7/23 4:01:00 PM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC

      SANTA MONICA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals Inc. (NASDAQ:OPNT) announced today the expiration of the waiting period under the United States (U.S.) Hart-Scott-Rodino Act of 1976, as amended (HSR Act), with respect to the previously announced agreement for Opiant to be acquired by Indivior PLC (LSE: INDV). The waiting period expired on February 2, 2023, without any action taken by the Federal Trade Commission (FTC). The HSR Act is a key U.S. antitrust statute that enables the FTC and Department of Justice (DOJ) to review proposed merger transactions by requiring the parties to observe a waiting period before closing their transaction. Completion of the tr

      2/6/23 8:00:00 AM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care